Analyst Ratings for MapLight Therapeutics (MPLT)
MPLT Rating Summary
MPLT Price Target Summary
- Highest: $43.00 (Needham)
- Lowest: $13.00 (UBS)
- Average: $29.33
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$29.33 (+113%)
* Over Last 12-Mos
Rating Score: 8.2 / 10
Percentile Rank: 84%
Avg. $ Target:
$29.33 (+113%)
* Over Last 12-Mos
Rating Score: 8.2 / 10
Percentile Rank: 84%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/10/2026 | UBS | Ashwani Verma | Downgrade | Neutral (Buy) |
13.00 (N/A) |
12.17 (13.77) |
13.15% | Details |
| 7/27/2026 | Morgan Stanley | Sean Laaman | Downgrade | Equalweight (Overweight) |
21.00 (34.00) |
34.00 (13.77) |
-59.5% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
